

Platinum-E Retroviral Packaging Cell Line, Ecotropic

CATALOG NUMBER: RV-101

STORAGE: Liquid nitrogen

Note: For best results begin culture of cells immediately upon receipt. If this is not possible, store at -80°C until first culture. Store subsequent cultured cells long term in liquid nitrogen.

QUANTITY & CONCENTRATION: 1.0 mL, $>3 \times 10^6$ cells/mL in DMEM, 20% FCS, and 10% DMSO

Background

Retroviruses are efficient tools for delivering heritable genes into the genome of dividing cells. However, conventional NIH-3T3 based retroviral packaging cell lines have limited stability and produce low viral yields, mainly due to poor expression level of the retroviral structure proteins (gag, pol, env) in the packaging cells.

The Platinum-E (Plat-E) Cell Line, a potent retrovirus packaging cell line based on the 293T cell line, was generated using novel packaging constructs with an EF1 α promoter to ensure longer stability and high-yield retroviral structure protein expression (gag, pol, ecotropic env). Plat-E cells can be kept in good condition in for at least 4 months in the presence of drug selection, and can produce retroviruses with an average titer of 1×10^7 infectious units/mL by transient transfection. In addition, replication competent retroviruses (RCR) are virtually nonexistent because only coding sequences of viral structural genes are used, avoiding any unnecessary retroviral sequences.

The Plat-E cell line is designed for rapid, transient production of high-titer ecotropic retrovirus.




Figure 1. NIH3T3 cells (left) and mouse ProB Ba/F3 cells (right) were infected with GFP retrovirus supernatant produced in Plat-E cells after transfection with pMX-GFP.

Medium

1. Culture Medium: DMEM, 10% fetal calf serum (FCS), 1 µg/mL puromycin, 10 µg/mL blasticidin, penicillin and streptomycin
2. Freeze Medium: 70% DMEM, 20% FBS, 10% DMSO

Methods

I. Establishing Plat-E Cultures from Frozen Cells

1. After quickly thawing the cells in a 37°C water bath, immediately transfer the thawed cell suspension into a 15 mL tube containing 10 mL of culture medium.
2. Centrifuge the tube for 5 min at 1300 to 1500 rpm.
3. Discard the supernatant and break the cell pellet by finger tapping.
4. Add a few drops of culture medium with gentle shaking and finger tap the tube a few times.
5. Add 2 mL of culture medium to the tube and gently pipet the cell suspension up and down twice.
6. Transfer the cell suspension to a 10 cm culture dish (Falcon® #3003 works well) containing 8 mL of culture medium.
7. Swirl the culture plate well to mix the cells, then incubate the cells for three days before expansion.

Important Notes:

- ***Don't change the culture medium during the first three days. It is normal to see some cells floating after the first 24 hours.***
- ***Don't culture cells to complete confluency. Split cells 4X to 6X every two to three days when the culture reaches 70-90% confluency.***

II. Splitting the Cells

Note: Avoid forming bubbles as much as possible during this procedure.

1. Wash cells once with PBS.
2. Add 4 mL of 0.05% Trypsin/0.5 mM EDTA solution to a 10 cm dish and incubate at 37°C for 3-5 min.
3. Remove the cells from the dish surface by tapping the rim of the culture dish.
4. Transfer 10 mL of the culture medium to a 50 mL tube.
5. Using the same pipette with some residual culture medium, wash the dish surface gently three times in 4 mL of the Trypsin/EDTA solution.
6. Gently pipette the cell suspension up and down 7 times and transfer the cell suspension into the 50 mL tube containing 10 mL medium from step 4.
7. Centrifuge the cells for 5 min at 1300-1500 rpm.
8. Discard the supernatant and break the cell pellet by finger tapping.
9. Add a few drops of culture medium with gentle shaking and finger tap the tube a few times.
10. Add 5 mL of culture medium and gently pipet the cell suspension up and down twice.
11. Add 15 mL of culture medium, then count and seed the cells. Typically 10^7 cells can be harvested from one 10 cm culture dish.

Transfection

1. Seed 2×10^6 cells in a 60 mm culture dish without antibiotics including puromycin and blasticidin one day before transfection.
2. After 16 to 24 hours, start transfection when the culture becomes 70-80% confluent.
Note: We suggest transfecting cells with FuGENE® Transfection Reagent (Promega) or Lipofectamine™ Plus (Invitrogen). For example, 3 µg retroviral expression plasmid is mixed with 9 µL FuGENE® Transfection Reagent according to the manufacturer's recommendation. The mixed DNA- FuGENE® complex is added by dropwise into the culture media.
3. Harvest retroviral supernatant 48 hours after transfection.

References

1. Morita, S., Kojim, T., and Kitamura, T. (2000) *Gene Therapy* **7**: 1063-1066.
2. Takahashi, K. and Yamanaka, S. (2006) *Cell* **126**: 663-676.

Recent Product Citations

1. Chao, J.L. et al. (2021). Effector T cell responses unleashed by regulatory T cell ablation exacerbate oral squamous cell carcinoma. *Cell Rep Med.* **2**(9): 100399. doi: 10.1016/j.xcrm.2021.100399.
2. Flommersfeld, S. et al. (2021). Fate mapping of single NK cells identifies a type 1 innate lymphoid-like lineage that bridges innate and adaptive recognition of viral infection. *Immunity.* doi: 10.1016/j.immuni.2021.08.002.
3. Eremenko, E. et al. (2021). An optimized protocol for the retroviral transduction of mouse CD4 T cells. *STAR Protoc.* **2**(3):100719. doi: 10.1016/j.xpro.2021.100719.
4. Li, C. et al. (2021). Interferon- α -producing plasmacytoid dendritic cells drive the loss of adipose tissue regulatory T cells during obesity. *Cell Metab.* doi: 10.1016/j.cmet.2021.06.007.
5. Lesch, S. et al. (2021). T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours. *Nat Biomed Eng.* doi: 10.1038/s41551-021-00737-6.
6. Dileepan, T. et al. (2021). MHC class II tetramers engineered for enhanced binding to CD4 improve detection of antigen-specific T cells. *Nat Biotechnol.* doi: 10.1038/s41587-021-00893-9.
7. Kim, K.P. et al. (2021). Donor cell memory confers a metastable state of directly converted cells. *Cell Stem Cell.* doi: 10.1016/j.stem.2021.02.023.
8. Dudek, M. et al. (2021). Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH. *Nature.* doi: 10.1038/s41586-021-03233-8.
9. Ferreira, A.C.F. et al. (2021). ROR α is a critical checkpoint for T cell and ILC2 commitment in the embryonic thymus. *Nat Immunol.* doi: 10.1038/s41590-020-00833-w.
10. Xu, N. et al. (2021). STING agonist promotes CAR T cell trafficking and persistence in breast cancer. *J Exp Med.* **218**(2):e20200844. doi: 10.1084/jem.20200844.
11. Yasuda, K. et al. (2021). Protein phosphatase 1 regulatory subunit 18 suppresses the transcriptional activity of NFATc1 via regulation of c-fos. *Bone Rep.* doi: 10.1016/j.bonr.2021.101114.
12. Seo, H. et al. (2021). BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells. *Nat Immunol.* **22**(8):983-995. doi: 10.1038/s41590-021-00964-8.
13. Marks, K.E. et al. (2021). Toll-like receptor 2 induces pathogenicity in Th17 cells and reveals a role for IPCEF in regulating Th17 cell migration. *Cell Rep.* **35**(13):109303. doi: 10.1016/j.celrep.2021.109303.

14. Bektik, E. et al. (2021). Inhibition of CREB-CBP Signaling Improves Fibroblast Plasticity for Direct Cardiac Reprogramming. *Cells*. **10**(7):1572. doi: 10.3390/cells10071572.
15. Bae, S. et al. (2021). MYC-mediated early glycolysis negatively regulates proinflammatory responses by controlling IRF4 in inflammatory macrophages. *Cell Rep*. **35**(11):109264. doi: 10.1016/j.celrep.2021.109264.
16. Lim, C.K. et al. (2021). Dimethyl sulfoxide (DMSO) enhances direct cardiac reprogramming by inhibiting the bromodomain of coactivators CBP/p300. *J Mol Cell Cardiol*. doi: 10.1016/j.yjmcc.2021.06.008.
17. Kim, C. et al. (2021). Histone deficiency and accelerated replication stress in T cell aging. *J Clin Invest*. **131**(11):143632. doi: 10.1172/JCI143632.
18. Xing, J. et al. (2021). Identification of poly(ADP-ribose) polymerase 9 (PARP9) as a noncanonical sensor for RNA virus in dendritic cells. *Nat Commun*. **12**(1):2681. doi: 10.1038/s41467-021-23003-4.
19. Rana, J. et al. (2021). CAR and TRuC redirected regulatory T cells differ in capacity to control adaptive immunity to FVIII. *Mol Ther*. doi: 10.1016/j.ymthe.2021.04.034.
20. Morimoto, A. et al. (2021). SLPI is a critical mediator that controls PTH-induced bone formation. *Nat Commun*. **12**(1):2136. doi: 10.1038/s41467-021-22402-x.
21. Marinaccio, C. et al. (2021). LKB1/STK11 is a tumor suppressor in the progression of myeloproliferative neoplasms. *Cancer Discov*. doi: 10.1158/2159-8290.CD-20-1353.
22. Lolla, P. et al. (2021). Inositol pyrophosphates promote MYC polyubiquitination by FBW7 to regulate cell survival. *Biochem J*. doi: 10.1042/BCJ20210081.
23. Ramirez-Martinez, A. et al. (2021). The nuclear envelope protein Net39 is essential for muscle nuclear integrity and chromatin organization. *Nat Commun*. **12**(1):690. doi: 10.1038/s41467-021-20987-x.
24. Riether, C. et al. (2021). Metoclopramide treatment blocks CD93-signaling-mediated self-renewal of chronic myeloid leukemia stem cells. *Cell Rep*. **34**(4):108663. doi: 10.1016/j.celrep.2020.108663.
25. Srivastava, S. et al. (2020). Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade. *Cancer Cell*. doi: 10.1016/j.ccell.2020.11.005.
26. Deng, Z. et al. (2020). Def6 regulates endogenous type-I interferon responses in osteoblasts and suppresses osteogenesis. *Elife*. **9**:e59659. doi: 10.7554/eLife.59659.
27. Zhang, H. et al. (2020). An IL-27-Driven Transcriptional Network Identifies Regulators of IL-10 Expression across T Helper Cell Subsets. *Cell Rep*. **33**(8):108433. doi: 10.1016/j.celrep.2020.108433.
28. Wu, D. et al. (2020). A method for expansion and retroviral transduction of mouse regulatory T cells. *J Immunol Methods*. doi: 10.1016/j.jim.2020.112931.
29. Wu, J. et al. (2020). Requisite Chromatin Remodeling for Myeloid and Erythroid Lineage Differentiation from Erythromyeloid Progenitors. *Cell Rep*. **33**(7):108395. doi: 10.1016/j.celrep.2020.108395.
30. Ni, X. et al. (2020). Death associated protein kinase 2 suppresses T-B interactions and GC formation. *Mol Immunol*. **128**:249-257. doi: 10.1016/j.molimm.2020.10.018.

Warranty

These products are warranted to perform as described in their labeling and in Cell Biolabs literature when used in accordance with their instructions. THERE ARE NO WARRANTIES THAT EXTEND BEYOND THIS EXPRESSED WARRANTY AND CELL BIOLABS DISCLAIMS ANY IMPLIED WARRANTY OF MERCHANTABILITY OR WARRANTY OF

FITNESS FOR PARTICULAR PURPOSE. CELL BIOLABS 's sole obligation and purchaser's exclusive remedy for breach of this warranty shall be, at the option of CELL BIOLABS, to repair or replace the products. In no event shall CELL BIOLABS be liable for any proximate, incidental or consequential damages in connection with the products.

License Information

This licensed product is intended for ACADEMIC, GOVERNMENT AND NON-PROFIT RESEARCH USE ONLY; not for use in diagnostic or therapeutic procedures. The product may not be transferred, sold, or otherwise provided to another laboratory except by an authorized distributor of Cell Biolabs, Inc.

Use of this product by Biotechnology and Pharmaceutical companies requires a license for all fields of use including research. Please contact:

Director of Business Development
Cell Biolabs, Inc.
busdev@cellbiolabs.com

Contact Information

Cell Biolabs, Inc.
7758 Arjons Drive
San Diego, CA 92126
Worldwide: +1 858-271-6500
USA Toll-Free: 1-888-CBL-0505
E-mail: tech@cellbiolabs.com
www.cellbiolabs.com

©2008-2021: Cell Biolabs, Inc. - All rights reserved. No part of these works may be reproduced in any form without permissions in writing.